IMMUTEP LIMITED - Announcements

Market Cap $486.6M Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMM	Change of Director's Interest Notice - M Voigt		19/09/24		Share
IMM	Webcast details for update on eftilagimod alpha (IMP321)		27/03/19		Share
IMM	Ceasing to be a substantial holder		26/03/19		Share
IMM	IMP761 Webcast Slides		25/03/19		Share
IMM	Immutep granted US patent for IMP321	PRICE SENSITIVE	22/03/19		Share
IMM	Webcast to discuss IMP761 preclinical results		19/03/19		Share
IMM	IMP761 results presented at ECCO conference	PRICE SENSITIVE	08/03/19		Share
IMM	Immutep receives A$872,351 R&D Tax Incentive	PRICE SENSITIVE	07/03/19		Share
IMM	Immutep doses First Patient in TACTI-002 Phase II Trial	PRICE SENSITIVE	06/03/19		Share
IMM	TACTI-mel data presented at World Immunotherapy Congress	PRICE SENSITIVE	06/03/19		Share
IMM	Immutep to present at Oppenheimer Healthcare Conference		04/03/19		Share
IMM	Half Year Accounts	PRICE SENSITIVE	27/02/19		Share
IMM	Immutep to present at upcoming industry conferences		26/02/19		Share
IMM	Immutep Presentation to Emergence Conference		25/02/19		Share
IMM	Immutep Investor Update		31/01/19		Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/19		Share
IMM	Immutep enters into collaboration with CYTLIMIC	PRICE SENSITIVE	07/01/19		Share
IMM	Change of Director's Interest Notice - Dr Howard		04/01/19		Share
IMM	Change of Director's Interest Notice - Mr Voigt		04/01/19		Share
IMM	Appendix 3B		02/01/19		Share
IMM	Becoming a substantial holder		24/12/18		Share
IMM	Disclosure Under LR 3.10.5A and 7.1A.4(b)		21/12/18		Share
IMM	Cleansing Notice		21/12/18		Share
IMM	Appendix 3B		21/12/18		Share
IMM	Cleansing prospectus for issue of warrants	PRICE SENSITIVE	20/12/18		Share
IMM	Immutep announces US$5.2 million capital raising	PRICE SENSITIVE	19/12/18		Share
IMM	European patent granted for IMP321 & antibody combinations	PRICE SENSITIVE	29/11/18		Share
IMM	Immutep granted European patent for IMP321	PRICE SENSITIVE	28/11/18		Share
IMM	Immutep presents new TACTI-mel data at ICI Europe Summit	PRICE SENSITIVE	27/11/18		Share
IMM	Change of Director's Interest Notice - Dr Howard		26/11/18		Share
IMM	Appendix 3B		21/11/18		Share
IMM	Results of Meeting		16/11/18		Share
IMM	2018 AGM CEO Presentation		16/11/18		Share
IMM	2018 AGM Chairman's Address		16/11/18		Share
IMM	Positive interim TACTI-mel data presented at SITC	PRICE SENSITIVE	12/11/18		Share
IMM	Operational Update	PRICE SENSITIVE	01/11/18		Share
IMM	AusBiotech Invest presentation slides		30/10/18		Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/18		Share
IMM	Data Presentations at Upcoming Industry Conferences		24/10/18		Share
IMM	Annual Report filed on Form 20-F with SEC		22/10/18		Share
IMM	Notice of Annual General Meeting/Proxy Form		11/10/18		Share
IMM	Annual Report to shareholders		11/10/18		Share
IMM	Appendix 4G & Corporate Governance Statement		11/10/18		Share
IMM	Appendix 3B & cleansing notice		04/10/18		Share
IMM	Appendix 3B & cleansing notice		03/10/18		Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		02/10/18		Share
IMM	Change of Director's Interest Notice - Mr Meyers		02/10/18		Share
IMM	Appendix 3B & cleansing notice		02/10/18		Share
IMM	Ceasing to be a substantial holder from AEF		02/10/18		Share
IMM	Immutep to present at SITC 2018		02/10/18		Share
IMM	Appendix 3B & cleansing notice		28/09/18		Share
IMM	Appendix 3B & cleansing notice		27/09/18		Share
IMM	Change in substantial holding from AEF		27/09/18		Share
IMM	Immutep to present at Ladenburg Thalmann conference		26/09/18		Share
IMM	Immutep enters into collaboration with Pfizer & Merck KGaA	PRICE SENSITIVE	24/09/18		Share
IMM	Immutep presentation for BioCentury NewsMakers conference		07/09/18		Share
IMM	Change in substantial holding from AEF		03/09/18		Share
IMM	Progress towards clinical development of IMP761	PRICE SENSITIVE	03/09/18		Share
IMM	Appendix 4E & 2018 Full Year Statutory Accounts	PRICE SENSITIVE	21/08/18		Share
IMM	Immutep receives A$1.9M from French R&D tax cash rebate	PRICE SENSITIVE	21/08/18		Share
IMM	Immutep to present at BioCentury NewsMakers conference		16/08/18		Share
IMM	TACTI-mel Patient Recruitment Complete & Operational Update	PRICE SENSITIVE	07/08/18		Share
IMM	Immutep secures Canadian patent grant for IMP731 antibody	PRICE SENSITIVE	07/08/18		Share
IMM	Immutep receives IND approval from US FDA for IMP321	PRICE SENSITIVE	31/07/18		Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/18		Share
IMM	Immutep submits IND application with FDA	PRICE SENSITIVE	02/07/18	214.46KB	Share
IMM	Immutep Investor Update		19/06/18	968.82KB	Share
IMM	Mid-point of patient enrolment reached in AIPAC trial	PRICE SENSITIVE	19/06/18	212.37KB	Share
IMM	Immutep Poster Presentations at ASCO		04/06/18	173.53KB	Share
IMM	Webcast slides for TACTI-mel clinical trial data	PRICE SENSITIVE	30/05/18	1.62MB	Share
IMM	New Data from Ongoing TACTI-mel Study	PRICE SENSITIVE	30/05/18	163.67KB	Share
IMM	3rd Annual Advances in Immuno-Oncology Congress Presentation		25/05/18	2MB	Share
IMM	Webcast to discuss interim results from TACTI-mel		17/05/18		Share
IMM	Response to ASX Price Query	PRICE SENSITIVE	15/05/18		Share
IMM	Immutep to present at ASCO		04/05/18		Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/18		Share
IMM	Appendix 3B		13/04/18		Share
IMM	Completion of Share Purchase Plan		13/04/18		Share
IMM	Operational Update	PRICE SENSITIVE	03/04/18		Share
IMM	Cambridge Healthtech Institute's I-O Summit Presentation		23/03/18		Share
IMM	Patient dosing commences in additional TACTI-mel cohort		22/03/18		Share
IMM	Becoming a substantial holder from AEF		19/03/18		Share
IMM	Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)		14/03/18		Share
IMM	Appendix 3B & Cleansing Notice		14/03/18		Share
IMM	Share Purchase Plan Offer Documents		13/03/18		Share
IMM	Immutep raises A$6.85M through institutional placement	PRICE SENSITIVE	12/03/18		Share
IMM	Immutep enters into collaboration with MSD	PRICE SENSITIVE	12/03/18		Share
IMM	US patent grant for IMP701 antibody	PRICE SENSITIVE	06/03/18		Share
IMM	Immutep receives A$686,704 R&D Tax Incentive	PRICE SENSITIVE	05/03/18		Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/18		Share
IMM	Outcome of DSMB Safety Review & Extension of TACTI-mel	PRICE SENSITIVE	09/02/18		Share
IMM	Immutep receives USD1M milestone payment from EOC	PRICE SENSITIVE	01/02/18		Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/18		Share
IMM	Change of Director's Interest Notice - Russell Howard		22/12/17		Share
IMM	Investor Update		21/12/17		Share
IMM	Operational Update	PRICE SENSITIVE	12/12/17		Share
IMM	Change of Director's Interest Notice - Mr Voigt		04/12/17		Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		04/12/17		Share
IMM	Appendix 3B		04/12/17		Share
IMM	Prima BioMed company name changed to Immutep		28/11/17		Share

IMM Change of Director's Interest Notice - M Voigt
19/09/24			Share
IMM Webcast details for update on eftilagimod alpha (IMP321)
27/03/19			Share
IMM Ceasing to be a substantial holder
26/03/19			Share
IMM IMP761 Webcast Slides
25/03/19			Share
IMM Immutep granted US patent for IMP321
22/03/19	PRICE SENSITIVE		Share
IMM Webcast to discuss IMP761 preclinical results
19/03/19			Share
IMM IMP761 results presented at ECCO conference
08/03/19	PRICE SENSITIVE		Share
IMM Immutep receives A$872,351 R&D Tax Incentive
07/03/19	PRICE SENSITIVE		Share
IMM Immutep doses First Patient in TACTI-002 Phase II Trial
06/03/19	PRICE SENSITIVE		Share
IMM TACTI-mel data presented at World Immunotherapy Congress
06/03/19	PRICE SENSITIVE		Share
IMM Immutep to present at Oppenheimer Healthcare Conference
04/03/19			Share
IMM Half Year Accounts
27/02/19	PRICE SENSITIVE		Share
IMM Immutep to present at upcoming industry conferences
26/02/19			Share
IMM Immutep Presentation to Emergence Conference
25/02/19			Share
IMM Immutep Investor Update
31/01/19			Share
IMM Appendix 4C - quarterly
24/01/19	PRICE SENSITIVE		Share
IMM Immutep enters into collaboration with CYTLIMIC
07/01/19	PRICE SENSITIVE		Share
IMM Change of Director's Interest Notice - Dr Howard
04/01/19			Share
IMM Change of Director's Interest Notice - Mr Voigt
04/01/19			Share
IMM Appendix 3B
02/01/19			Share
IMM Becoming a substantial holder
24/12/18			Share
IMM Disclosure Under LR 3.10.5A and 7.1A.4(b)
21/12/18			Share
IMM Cleansing Notice
21/12/18			Share
IMM Appendix 3B
21/12/18			Share
IMM Cleansing prospectus for issue of warrants
20/12/18	PRICE SENSITIVE		Share
IMM Immutep announces US$5.2 million capital raising
19/12/18	PRICE SENSITIVE		Share
IMM European patent granted for IMP321 & antibody combinations
29/11/18	PRICE SENSITIVE		Share
IMM Immutep granted European patent for IMP321
28/11/18	PRICE SENSITIVE		Share
IMM Immutep presents new TACTI-mel data at ICI Europe Summit
27/11/18	PRICE SENSITIVE		Share
IMM Change of Director's Interest Notice - Dr Howard
26/11/18			Share
IMM Appendix 3B
21/11/18			Share
IMM Results of Meeting
16/11/18			Share
IMM 2018 AGM CEO Presentation
16/11/18			Share
IMM 2018 AGM Chairman's Address
16/11/18			Share
IMM Positive interim TACTI-mel data presented at SITC
12/11/18	PRICE SENSITIVE		Share
IMM Operational Update
01/11/18	PRICE SENSITIVE		Share
IMM AusBiotech Invest presentation slides
30/10/18			Share
IMM Appendix 4C - quarterly
25/10/18	PRICE SENSITIVE		Share
IMM Data Presentations at Upcoming Industry Conferences
24/10/18			Share
IMM Annual Report filed on Form 20-F with SEC
22/10/18			Share
IMM Notice of Annual General Meeting/Proxy Form
11/10/18			Share
IMM Annual Report to shareholders
11/10/18			Share
IMM Appendix 4G & Corporate Governance Statement
11/10/18			Share
IMM Appendix 3B & cleansing notice
04/10/18			Share
IMM Appendix 3B & cleansing notice
03/10/18			Share
IMM Change of Director's Interest Notice - Mr Chamberlain
02/10/18			Share
IMM Change of Director's Interest Notice - Mr Meyers
02/10/18			Share
IMM Appendix 3B & cleansing notice
02/10/18			Share
IMM Ceasing to be a substantial holder from AEF
02/10/18			Share
IMM Immutep to present at SITC 2018
02/10/18			Share
IMM Appendix 3B & cleansing notice
28/09/18			Share
IMM Appendix 3B & cleansing notice
27/09/18			Share
IMM Change in substantial holding from AEF
27/09/18			Share
IMM Immutep to present at Ladenburg Thalmann conference
26/09/18			Share
IMM Immutep enters into collaboration with Pfizer & Merck KGaA
24/09/18	PRICE SENSITIVE		Share
IMM Immutep presentation for BioCentury NewsMakers conference
07/09/18			Share
IMM Change in substantial holding from AEF
03/09/18			Share
IMM Progress towards clinical development of IMP761
03/09/18	PRICE SENSITIVE		Share
IMM Appendix 4E & 2018 Full Year Statutory Accounts
21/08/18	PRICE SENSITIVE		Share
IMM Immutep receives A$1.9M from French R&D tax cash rebate
21/08/18	PRICE SENSITIVE		Share
IMM Immutep to present at BioCentury NewsMakers conference
16/08/18			Share
IMM TACTI-mel Patient Recruitment Complete & Operational Update
07/08/18	PRICE SENSITIVE		Share
IMM Immutep secures Canadian patent grant for IMP731 antibody
07/08/18	PRICE SENSITIVE		Share
IMM Immutep receives IND approval from US FDA for IMP321
31/07/18	PRICE SENSITIVE		Share
IMM Appendix 4C - quarterly
30/07/18	PRICE SENSITIVE		Share
IMM Immutep submits IND application with FDA
02/07/18	PRICE SENSITIVE	214.46KB	Share
IMM Immutep Investor Update
19/06/18		968.82KB	Share
IMM Mid-point of patient enrolment reached in AIPAC trial
19/06/18	PRICE SENSITIVE	212.37KB	Share
IMM Immutep Poster Presentations at ASCO
04/06/18		173.53KB	Share
IMM Webcast slides for TACTI-mel clinical trial data
30/05/18	PRICE SENSITIVE	1.62MB	Share
IMM New Data from Ongoing TACTI-mel Study
30/05/18	PRICE SENSITIVE	163.67KB	Share
IMM 3rd Annual Advances in Immuno-Oncology Congress Presentation
25/05/18		2MB	Share
IMM Webcast to discuss interim results from TACTI-mel
17/05/18			Share
IMM Response to ASX Price Query
15/05/18	PRICE SENSITIVE		Share
IMM Immutep to present at ASCO
04/05/18			Share
IMM Appendix 4C - quarterly
23/04/18	PRICE SENSITIVE		Share
IMM Appendix 3B
13/04/18			Share
IMM Completion of Share Purchase Plan
13/04/18			Share
IMM Operational Update
03/04/18	PRICE SENSITIVE		Share
IMM Cambridge Healthtech Institute's I-O Summit Presentation
23/03/18			Share
IMM Patient dosing commences in additional TACTI-mel cohort
22/03/18			Share
IMM Becoming a substantial holder from AEF
19/03/18			Share
IMM Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
14/03/18			Share
IMM Appendix 3B & Cleansing Notice
14/03/18			Share
IMM Share Purchase Plan Offer Documents
13/03/18			Share
IMM Immutep raises A$6.85M through institutional placement
12/03/18	PRICE SENSITIVE		Share
IMM Immutep enters into collaboration with MSD
12/03/18	PRICE SENSITIVE		Share
IMM US patent grant for IMP701 antibody
06/03/18	PRICE SENSITIVE		Share
IMM Immutep receives A$686,704 R&D Tax Incentive
05/03/18	PRICE SENSITIVE		Share
IMM Half Yearly Report and Accounts
22/02/18	PRICE SENSITIVE		Share
IMM Outcome of DSMB Safety Review & Extension of TACTI-mel
09/02/18	PRICE SENSITIVE		Share
IMM Immutep receives USD1M milestone payment from EOC
01/02/18	PRICE SENSITIVE		Share
IMM Appendix 4C - quarterly
22/01/18	PRICE SENSITIVE		Share
IMM Change of Director's Interest Notice - Russell Howard
22/12/17			Share
IMM Investor Update
21/12/17			Share
IMM Operational Update
12/12/17	PRICE SENSITIVE		Share
IMM Change of Director's Interest Notice - Mr Voigt
04/12/17			Share
IMM Change of Director's Interest Notice - Mr Chamberlain
04/12/17			Share
IMM Appendix 3B
04/12/17			Share
IMM Prima BioMed company name changed to Immutep
28/11/17			Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 28.5¢		Change -0.020(6.56%)		Mkt cap ! $486.6M

Open	High	Low	Value	Volume
30.5¢	30.5¢	28.5¢	$913.3K	3.099M

Buyers (Bids)

No.	Vol.	Price($)
6	124895	28.5¢

Sellers (Offers)

Price($)	Vol.	No.
29.0¢	30287	2

View Market Depth

No.	Vol.	Price($)
4	115519	0.395
3	76000	0.390
4	68064	0.385
10	225656	0.380
1	8500	0.375

Price($)	Vol.	No.
0.405	37481	2
0.410	240538	10
0.415	229395	10
0.420	502644	9
0.425	50700	3

Last trade - 16.10pm 21/11/2024 (20 minute delay)


Last 28.5¢		Change -0.020 ( 6.80 %)
Open	High	Low	Volume
30.5¢	30.5¢	28.5¢	1420446
Last updated 15.59pm 21/11/2024 ?

IMM (ASX) Chart